C1 Cont'd

abandoned; which is a continuation of Serial No. [07]~~06/314,214~~, 06/314,124
filed October 23, 1981, now abandoned. --

In the Claims:

C2

53. (amended) A method of developing oligodeoxyribonucleotide therapeutic agents for use in *in vivo* inhibition of the synthesis of one or more targeted proteins in a cell without substantially inhibiting the synthesis of non-targeted proteins, comprising the steps of:

determining the base sequence of an organism's messenger ribonucleic acid, said base sequence coding for at least a portion of said protein targeted for inhibition;

synthesizing an oligodeoxyribonucleotide, the nucleotide sequence of which is substantially complementary to at least a portion of said base sequence and capable of hybridization with said messenger ribonucleic acid base sequence coding for at least a portion of a protein targeted for inhibition so as to substantially block translation of said base sequence and inhibit synthesis of said targeted protein after introducing into the cells of said organism, and

at least a portion of said oligodeoxyribonucleotide being in a [more stable] stabilized form in order to limit degradation *in vivo*.

54. (amended) The method of claim 53, wherein said [more stable] stabilized form is a phosphotriester form.

Please cancel claim 62.

REMARKS

Applicant notes the claims numbered as 84-93, which were added to the application in the Preliminary Amendment filed on December 20, 1990, should have been identified as claims 53-